Antibody phage-display development platform - human scfv, llama VHH, synthetic VHH

KRABS Biotechnology is a Brazilian startup that specializes in the development of recombinant antibodies using Phage Display technology. By utilizing libraries of scFv and nanobodies, the company offers a research and development platform that eliminates the need for animal testing. This approach is designed to produce monoclonal antibodies for various applications in human and animal health, including drug development, in vitro diagnostics, and environmental monitoring, while providing a more ethical and sustainable process compared to traditional methods.

The company is recognized for developing a topical chimeric antibody therapy for atopic dermatitis, which targets the human kallikrein 7 (KLK7) enzyme. This drug, formulated as a hydrogel, has secured patent protection in the United States, with additional applications in Brazil and Europe. By addressing the limitations of existing systemic treatments, such as side effects and patient resistance, KRABS aims to provide an innovative alternative for dermatological conditions. The startup, supported by FAPESP research programs, collaborates with academic institutions to advance its pipeline and facilitate the production of its biotechnological assets.